Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children under the age of 16. This autoimmune disease is characterised by persistent joint inflammation. The typical signs of joint inflammation are pain, swelling and limitation of movement.. There are several forms of JIA. They are mainly distinguished by the number of joints affected at presentation (e.g oligoarticular – less than 5 joints - or polyarticular JIA – 5 or more joints) and by the presence of additional symptoms such as fever, rash and others (Psoriatric arthritis, systemic JIA). Treatment is based mainly on the use of drugs that inhibit articular and/or systemic inflammation and physiotherapy. The therapeutic possibilities for pediatric rheumatology patients have expended since 2000 (with the introduction of biological therapies). However, some children seem to be "treatment resistant", meaning that the disease is still active and the joints inflamed despite intensive treatment. Therefore, the search of alternative therapies is still needed.
Study to Evaluate the Safety and Efficacy of Baricitinib in Patients with Juvenile Idiopathic Arthritis (Lilly)
Principal Investigator: Prof. Carine Wouters/ Prof. Lien De Somer
JAHV: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA).
JAHX: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA).
JAHU: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less Than 18 Years Old with Systemic Juvenile Idiopathic Arthritis.
RHCG: Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis.
Pediatric rheumatologic inflammatory disease (JIR)
Principal Investigators: Prof. Carine Wouters/ Prof. Lien De Somer